Participants reported improvements in mobility, physical activity capacity, and energy levels throughout treatment despite substantial weight reduction
Choose Atorvastatin for patients with significant renal impairment, when leveraging its extensive outcome data, or for formulary/cost-effectiveness reasons
Charles Brenner, who discovered nicotinamide riboside as an NAD+ precursor, conducted a 2016 clinical trial showing oral NR supplementation safely increased human blood NAD+ levels up to 2.7-fold [14]
Chtnie odpowiemy nawet na najtrudniejsze pytania
10.1084/jem.20210235 49 ForresterS
However, GLP-1s need to be studied more and on a wider scale. Hsiangkuo Yuan, MD, PhD, study co-author and clinical research director at Jefferson Headache Center, agrees, noting that if someone already has obesity and struggles with migraines, taking a GLP-1 may help with both issues